{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.6","upperLimit":"34.5","value":"22.6"},{"groupId":"OG001","lowerLimit":"10.6","upperLimit":"31.5","value":"20"}]}],"title":"180 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.9","upperLimit":"43.2","value":"30.4"},{"groupId":"OG001","lowerLimit":"12.6","upperLimit":"34.3","value":"22.5"}]}],"title":"365 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Defined by either morphological, cytogenetic/molecular or radiological evidence of disease consistent with pre-HCT features. A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first). The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"180 days and 365 days post-transplant","title":"Cumulative Incidence of Relapse/Progression","type":"SECONDARY","unitOfMeasure":"percentage of participants"}